SCHEMBL23973279

SCHEMBL23973279

CC(C)(C)OC(=O)N1Cc2nc(C3(c4ccccc4)CC3)[nH]c(=O)c2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
PARP1 P09874 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
TSHR P16473 2/20 0.40
ALOX15 P16050 1/20 0.40
C5AR1 P21730 1/20 0.40
DDB1 Q16531 2/20 0.39
CRBN Q96SW2 2/20 0.39
ATM Q13315 1/20 0.38
TACR1 P25103 1/20 0.38
CYP11B2 P19099 1/20 0.37
MAPK1 P28482 1/20 0.36
MTHFD2 P13995 1/20 0.36
RORC P51449 1/20 0.36
KIT P10721 1/20 0.36
SCD5 Q86SK9 1/20 0.36
CCR5 P51681 1/20 0.36
SPR P35270 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23973278 0.89 PARP1 (0.43) OPRD1OPRK1PARP1TNKS2PARP2
SCHEMBL23973274 0.89 SPR (0.42) OPRD1OPRK1PARP1TNKS2PARP2
SCHEMBL1622911 0.86 OPRD1 (0.44) OPRD1OPRK1PARP1TNKS2PARP2
SCHEMBL23973298 0.86 MTHFD2 (0.46) OPRD1OPRK1PARP1TNKS2PARP2
SCHEMBL23973303 0.84 MTHFD2 (0.44) PARP1TNKS2PARP2CRBNMTHFD2
SCHEMBL23973044 0.84 OPRD1 (0.39) OPRD1OPRK1PARP1TNKS2TSHR
SCHEMBL23972930 0.82 PARP1 (0.40) PARP1TNKS2PARP2DDB1CRBN
SCHEMBL23972843 0.81 SPR (0.38) OPRD1OPRK1PARP1TNKS2PARP2
SCHEMBL30604380 0.81 SPR (0.38) OPRD1OPRK1PARP1TNKS2PARP2
SCHEMBL23973006 0.81 F12 (0.41) PARP1TNKS2PARP2C5AR1DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 OPRD1 82/4885OPRK1 47/4885PARP1 2542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.